An interventional study of Lung Ultrasound and Sham in Lower Resp Tract Infection, sponsored by American University of Beirut Medical Center. Recruiting at 1 site in Lebanon. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by American University of Beirut Medical Center · Not applicable, Interventional, and Prevention
Title: Effect of Pediatric Lung Ultrasound on Antibiotic Prescriptions in Hospitalized Children and Adolescents with Lower Respiratory Tract Infections (PLUS-AP Trial)
Purpose of the Study:
This study is being done to find out if a type of imaging called lung ultrasound (LUS) can help doctors decide when to stop antibiotics in children and teens who are in the hospital with lung infections, like pneumonia. Antibiotics are often given to these patients, but sometimes they are used for longer than necessary, which can be harmful. The investigators want to see if using LUS helps doctors make decisions that reduce unnecessary antibiotic use, which can help prevent antibiotic resistance and other complications.
What is Lung Ultrasound (LUS)? Lung ultrasound is a safe, non-invasive, and painless test that uses sound waves to look at the lungs. It doesn't involve radiation like chest X-rays. It is already being used to help doctors understand lung conditions, and this study will test if it can also help in deciding when to stop antibiotics.
How the Study Works:
Participants: Children and adolescents (ages 3 months-18 years) who are admitted to the hospital with a lung infection.
Groups:
LUS Group: These patients will have a lung ultrasound within 24 hours of enrollment. The results will help guide decisions about when to stop antibiotics.
Standard Care Group: These patients will receive regular hospital care, which may include chest X-rays and other tests to guide their treatment.
What Will Be Measured?
Primary Goal: The study will measure how long children and teens stay on antibiotics. The investigators are testing whether LUS can help shorten this time without affecting their recovery.
Secondary Goals: Investigators will also look at how long patients stay in the hospital, whether they need further treatment or care after leaving.
Why is This Important? If this study shows that LUS can safely reduce the use of antibiotics, it could change how doctors treat lung infections in children. Reducing unnecessary antibiotic use can help fight antibiotic resistance and protect children from side effects of unnecessary treatments.
The PLUS-AP Trial (Pediatric Lung Ultrasound to Guide Antibiotic Prescriptions for Hospitalized Children and Adolescents with Lower Respiratory Tract Infections) is a randomized controlled trial designed to assess the effect of pediatric lung ultrasound (LUS) on antibiotic prescribing practices for children and adolescents hospitalized with lower respiratory tract infections (LRTIs). This study aims to explore whether incorporating LUS into clinical decision-making can reduce the unnecessary use of antibiotics without compromising patient care.
Background:
Antibiotics are frequently overprescribed for LRTIs in pediatric populations, contributing to antibiotic resistance and unnecessary adverse events. While chest X-rays are commonly used to diagnose LRTIs, they can be resource-intensive and involve radiation exposure. Lung ultrasound (LUS) is a non-invasive, radiation-free imaging modality that has gained recognition for its utility in diagnosing and monitoring respiratory diseases. This trial will evaluate whether LUS can assist clinicians in making more accurate diagnostic decisions and potentially reduce the use of antibiotics in hospitalized pediatric patients with LRTIs.
Study Objectives:
Primary Objective: To assess whether the use of pediatric lung ultrasound (LUS) reduces the duration of antibiotic treatment in hospitalized children and adolescents diagnosed with LRTIs.
Secondary Objectives:
To evaluate the impact of LUS on the length of hospital stay. To compare clinical outcomes such as the need for escalation to invasive respiratory support, mortality, and readmission rates between the LUS and standard care groups.
To assess the cost-effectiveness of LUS implementation in managing pediatric LRTIs.
Study Design:
The PLUS-AP trial is designed as a phase III, randomized, controlled, patient blinded, single center superiority trial with two parallel groups and a primary endpoint of antibiotic prescriptions by the day of discharge from the hospital. Randomization will be performed as permuted block randomization with a 1:1 allocation.
LUS Group: Participants will undergo lung ultrasound within 24 hours of enrollment, and the results will be used to guide antibiotic therapy decisions, including the duration of antibiotic treatment.
Standard Care Group: Participants will receive standard care, which includes clinical evaluation and any other diagnostic tests, such as chest X-ray, as deemed necessary by the treating physician.
Study Population:
Inclusion Criteria:
Exclusion Criteria:
Study Interventions:
Lung Ultrasound (LUS): The ultrasound will be exclusively performed by the principal investigator (A.I.), who has credentialing in LUS with more than 4 years of experience, and will be blinded to CXR results. It will take less than 15 minutes, with follow-up scans conducted within 48 hours or prior to discharge to monitor disease progression.
Standard Care: The control group will follow typical hospital procedures, with diagnosis and treatment guided by clinical examination and routine diagnostic tests such as chest X-ray.
Outcome Measures:
Primary Outcome: investigate the effect of adding LUS to standard care on the endpoint of antibiotic prescriptions upon discharge in children hospitalized with LRTIs, compared to standard care and SLUS.
Secondary Outcomes:
To investigate the effect of adding LUS to standard care, as compared to standard care with SLUS, on the end points of:
Trial design
Expected Impact:
The results of this trial could potentially change clinical practices by providing evidence supporting the use of LUS in reducing unnecessary antibiotic use, thereby reducing the burden of antibiotic resistance in pediatric populations. It could also contribute to the safe and more efficient management of LRTIs in hospitalized children and adolescents.
Estimated Study Timeline:
Study Start Date: april 2025 Study Completion Date: noveber 2026
Sponsor and Investigators:
Principal Investigator: Dr. Ali Ismail Co-Investigators: Dr. Marianne Majdalani, Dr. Jihane Moukhaiber, and others.
American University of Beirut Medical Center is the lead sponsor of 158 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will undergo a lung ultrasound within 24 hours of enrollment. The results of this ultrasound will be used to help guide decisions about when to stop antibiotic therapy, aiming to reduce unnecessary antibiotic use.
Device: Lung Ultrasound
Participants in this group will receive the standard clinical care for lower respiratory tract infections, which may include diagnostic tests such as chest X-ray, with antibiotic therapy managed according to the usual clinical protocols.
Device: Sham
Lung ultrasound (LUS) is a non-invasive, radiation-free imaging technique that uses sound waves to visualize the lungs. It will be used in the experimental arm to help guide decisions regarding antibiotic therapy in hospitalized children and adolescents with lower respiratory tract infections (LRTIs). The LUS will be performed within 24 hours of enrollment.
In the sham group, participants will undergo a mock or placebo version of the lung ultrasound. This involves performing the procedure in a way that mimics the real ultrasound process but does not provide any diagnostic results or influence clinical decision-making regarding antibiotic therapy.
Antibiotic Prescription Rate Upon Discharge
The primary outcome is the rate of antibiotic prescriptions at the time of discharge. This will compare the proportion of children and adolescents with lower respiratory tract infections (LRTIs) who are prescribed antibiotics upon discharge in the experimental group (Lung Ultrasound \[LUS\]) versus the control group (Sham Lung Ultrasound \[SLUS\]) or standard care. The aim is to assess whether the use of LUS can reduce unnecessary antibiotic prescriptions at discharge.
Time frame: Upon discharge (up to 30 days).
Plan to share: Yes — De-identified individual participant data underlying the results reported in the publication, including demographic characteristics, baseline clinical data, intervention allocation, outcome measures, and the study data dictionary.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Beginning 6 months after publication of the primary study results and ending 5 years after publication.
Access criteria: De-identified individual participant data underlying the published results will be made available to qualified researchers who submit a methodologically sound research proposal. Requests should be directed to the corresponding investigator. Access will be granted following review and approval by the study investigators and execution of an appropriate data sharing agreement, in accordance with institutional policies, ethical requirements, and applicable regulations.
Started Apr 2025 (actual). Primary completion is estimated for Jun 2027, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
American University of Beirut Medical Center →